Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or survival after a median five years of follow-up, according to results from the BOOG 2013-08 phase III clinical trial, presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.
More...
Hybrid Mode
